| Serial Number | 98229386 |
| Word Mark | OCENLO |
| Filing Date | Wednesday, October 18, 2023 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, October 1, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 6, 2024 |
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; pharmaceutical preparations for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations; diagnostic agents, preparations and substances for medical purposes; radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; radio-isotope markers for therapeutic or diagnostic use. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, October 24, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Party Name | Bristol-Myers Squibb Company |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543 |
| Event Date | Event Description |
| Thursday, May 30, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, June 11, 2024 | PRIORITY ACTION WRITTEN |
| Saturday, October 21, 2023 | NEW APPLICATION ENTERED |
| Tuesday, October 24, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, January 23, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, January 23, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, January 23, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, June 11, 2024 | PRIORITY ACTION E-MAILED |
| Tuesday, June 11, 2024 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Wednesday, June 26, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 26, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, June 26, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, June 29, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, July 17, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 6, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, August 6, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 1, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |